Curanex Pharmaceuticals Closes $15M IPO on Nasdaq Capital Market.

Curanex Pharmaceuticals Inc. has announced the closing of its initial public offering, raising $15 million in gross proceeds. The company issued 3,750,000 shares of common stock at a public offering price of $4.00 per share. Curanex's shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025. The company granted the underwriters an option to purchase additional shares within 45 days.

Curanex Pharmaceuticals Inc. has successfully closed its initial public offering (IPO), raising $15 million in gross proceeds. The company issued 3,750,000 shares of common stock at a public offering price of $4.00 per share. Curanex's shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025. The underwriters, including Dominari Securities LLC, Pacific Century Securities LLC, and Revere Securities LLC, have been granted an option to purchase up to 562,500 additional shares within 45 days of the offering's close [1].

Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York. The company focuses on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China. The company plans to use the proceeds from the IPO to support FDA-required toxicology and pharmacokinetic studies, preparation and submission of an Investigational New Drug application, and general corporate purposes [2].

The company's registration statement was declared effective by the SEC on August 12, 2025. The IPO was conducted on a firm commitment basis, and the final prospectus is available on the SEC's website [2]. Investors are encouraged to review the final prospectus for more complete information about the company and the offering.

References:
[1] https://www.investing.com/news/stock-market-news/curanex-pharmaceuticals-prices-ipo-at-4-per-share-432SI-4210718
[2] https://www.morningstar.com/news/globe-newswire/9519418/curanex-pharmaceuticals-inc-announces-closing-of-its-initial-public-offering